BTIG Research Cuts Stryker (NYSE:SYK) Price Target to $379.00

Stryker (NYSE:SYK) had its price target cut by research analysts at BTIG Research from $397.00 to $379.00 in a research report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the medical technology company’s stock. BTIG Research’s price objective indicates a potential upside of 20.46% from the stock’s current price.

Several other analysts have also commented on SYK. Leerink Partners started coverage on shares of Stryker in a research report on Monday, April 13th. They set an “outperform” rating and a $410.00 price target on the stock. Truist Financial reduced their price target on shares of Stryker from $395.00 to $380.00 and set a “hold” rating on the stock in a research report on Wednesday, April 15th. Wall Street Zen lowered shares of Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. Evercore set a $390.00 target price on Stryker in a research report on Monday, January 5th. Finally, Barclays reissued an “overweight” rating and issued a $469.00 target price on shares of Stryker in a research report on Monday, February 2nd. Fifteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $418.26.

Stryker Stock Down 0.2%

SYK stock opened at $314.64 on Friday. The firm has a market cap of $120.50 billion, a PE ratio of 37.46, a PEG ratio of 1.84 and a beta of 0.92. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. The firm’s 50 day moving average price is $345.67 and its 200-day moving average price is $356.95. Stryker has a one year low of $311.31 and a one year high of $404.87.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities research analysts anticipate that Stryker will post 14.91 EPS for the current year.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the sale, the director owned 2,457,331 shares of the company’s stock, valued at $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Stryker

A number of institutional investors and hedge funds have recently modified their holdings of SYK. Norges Bank acquired a new position in shares of Stryker during the fourth quarter worth $1,822,272,000. Auto Owners Insurance Co raised its holdings in shares of Stryker by 35,047.0% in the fourth quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock valued at $1,024,444,000 after buying an additional 2,906,448 shares during the last quarter. Wellington Management Group LLP raised its holdings in Stryker by 22.6% during the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock worth $2,282,192,000 after purchasing an additional 1,198,665 shares in the last quarter. Corient Private Wealth LLC raised its holdings in Stryker by 104.4% during the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after purchasing an additional 1,146,998 shares in the last quarter. Finally, Alliancebernstein L.P. raised its holdings in Stryker by 13.3% during the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after purchasing an additional 741,542 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Key Headlines Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Management kept FY‑2026 guidance intact — organic sales growth of 8%–9.5% and adjusted EPS of $14.90–$15.10, signaling confidence in medium‑term demand and execution. Stryker maintains 2026 outlook
• Positive Sentiment: Cash flow and GAAP net income showed strength (operating cash from ops surged year‑over‑year; reported profit rose to $745M), providing balance‑sheet flexibility. Q1 results: cash flow & net income up
• Positive Sentiment: Company says it has largely recovered operationally from the cyber incident, which management says disrupted the quarter but is being contained. That supports the decision to keep guidance. Stryker reports first quarter 2026 operating results
• Neutral Sentiment: Full Q1 press conference transcript and management commentary are available for details on recovery timing, regional trends and product‑line performance — useful for assessing forward visibility. Q1 2026 press conference transcript
• Negative Sentiment: Q1 adjusted EPS of $2.60 missed the consensus (~$2.98) and revenue of $6.02B fell short of estimates (~$6.34B), a headline miss that pressured the stock. Q1 earnings snapshot / consensus miss
• Negative Sentiment: Management cited softer demand for implants and complex‑procedure devices (orthopaedics, spine) and adjusted operating margin contraction (~180 bps), suggesting near‑term revenue headwinds even as recovery from the cyber event continues. Reuters: misses estimates on muted demand

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.